Home Depot Gets Price Target Cuts By Analysts After Downbeat Sales

Home Depot Inc (NYSE: HD) reported mixed first-quarter financial results.

Home Depot Inc (NYSE:HD) reported mixed first-quarter financial results.

Home Depot reported a first sales decline of 4.2% year-on-year to $37.26 billion, missing the analyst consensus estimate of $38.31 billion. EPS of $3.82 beat the analyst consensus of $3.80.

Home Depot sees sales and comparable sales decline of 2% – 5% vs. the $156.56 billion estimate. The outlook was lowered from the flat revenue growth anticipated in the fourth quarter.

Home Depot shares fell 2.2% to close at $282.33 on Tuesday.

These analysts made changes to their price targets on Home Depot following earnings announcement.

  • Telsey Advisory Group cut the price target on Home Depot from $340 to $315. Telsey Advisory Group analyst Joseph Feldman maintained an Outperform rating.
  • Goldman Sachs lowered the price target on Home Depot from $340 to $330. Goldman Sachs analyst Kate McShane maintained a Buy rating
  • Credit Suisse cut Home Depot price target from $320 to $310. Credit Suisse analyst Karen Short maintained the stock with a Neutral.

 

Now Read This: Fear & Greed Index Moves To 'Neutral' Zone After Dow Dips Over 300 Points

Total
0
Shares
Related Posts
Read More

Annji Pharmaceutical Has Entered Into An Exclusive License Agreement With Avenue Therapeutics For AJ201 For Spinal And Bulbar Muscular Atrophy, Also Known As Kennedy’s Disease; Upfront Payment Of $3M, Milestone Payments Of Upto $250M

The deal covers the U.S., Canada, European Union, Great Britain, And Israel. Avenue will also issue 831,618 shares as equity upfront and additional shares upon the achievement of a clinical milestone, aggregating

ATXI